+ Watch OXGN
on My Watchlist
A biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases.
For Christmas this year, you may want to consider giving that special someone a short position in Oxigene. It's the gift that keeps on giving. Zybrestat has failed and failed and failed yet somehow the stock still pops every time the company finds something to do with it. This time it's a partnership for compassionate use of Zybrestat in Europe. I'm not sure how compassionate it is to treat a desperate patient with a drug that has failed to show any significant benefit over placebo and will never be approved by the FDA or EMEA, but I guess that's for the patients and doctors to decide. Meanwhile, Oxigene continues to float their pie-in-the-sky phase III trial of Zybrestat, but in order to fund the trial they'll have to dilute enough to become the next Cell Therapeutics.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions